Drug patents …
… from Kazakhstan to Kalamazoo
Anticipate generic drug launch
Deep knowledge on
small-molecule drugs and
the 110,000 global patents
Manage your formulary budget
Proactively manage your pharmacy inventory
Find generic entry opportunities
Flat-rate pricing for predictable budgeting
Short-term plans for project- or client-based billing
Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing
|Title:||Controlled release auris sensory cell modulator compositions and methods for the treatment of otic disorders|
|Abstract:||Disclosed herein are thermoreverisble gel compositions containing a multiparticulate glutamate receptor antagonist, and methods for the treatment of otic diseases or conditions through intratympanic administration of the composition to an individual afflicted with an otic disease or condition.|
|Inventor(s):||Lichter; Jay (Rancho Santa Fe, CA), Trammel; Andrew M. (Olathe, KS), Piu; Fabrice (San Diego, CA), Ye; Qiang (San Diego, CA), Vollrath; Benedikt (San Diego, CA), Dellamary; Luis A. (San Marcos, CA), Lebel; Carl (Malibu, CA), Harris; Jeffrey P. (La Jolla, CA)|
|Assignee:||OTONOMY, INC. (San Diego, CA) THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (Oakland, CA)|
|Filing Date:||Jun 26, 2013|
|Claims:||1. A sterile aqueous pharmaceutical composition for use in the treatment of otic disorders by intratympanic administration on or near the round window membrane of the ear, the pharmaceutical composition comprising an auris acceptable thermoreversible gel and a multiparticulate non-microencapsulated glutamate receptor antagonist, wherein sustained release of the glutamate receptor antagonist into the cochlea occurs for a period of at least 5 days. |
2. The pharmaceutical composition of claim 1, wherein the thermoreversible gel comprises a copolymer of polyoxyethylene and polyoxypropylene.
3. The composition of claim 2, wherein the copolymer of polyoxyethylene and polyoxypropylene is Poloxamer 407.
4. The composition of claim 1, wherein the thermoreversible gel has a gelation temperature between about room temperature and about body temperature.
5. The composition of claim 1, wherein the thermoreversible gel has a non-gelation viscosity that allows injection at or about room temperature with a needle having a gauge in the range of 18-31 through the tympanic membrane to an area on or near the round window membrane.
6. The composition of claim 5, wherein the thermoreversible gel has a gelation viscosity between about 15,000 cP and about 1,000,000 cP.
7. The composition of claim 1, wherein the glutamate receptor antagonist is essentially in the form of micronized particles.
8. The composition of claim 1, wherein the glutamate receptor antagonist is 1-aminoadamantane; dextromethorphan; dextrorphan; ibogaine; ifenprodil; (S)-ketamine; (R)-ketamine; memantine; dizocilpine (MK-801); gacyclidine; traxoprodil; D-2-amino-5-phosphonopentanoic acid (D-AP5); 3-((.+-.)2-carboxypiperazin-4-yl)-propyl-1-phosphonic acid (CPP); conantokin; 7-chlorokynurenate (7-CK); licostinel; nitrous oxide; phencyclidine; riluzole; tiletamine; aptiganel; remacimide; DCKA (5,7-dichlorokynurenic acid); kynurenic acid; 1-aminocyclopropanecarboxylic acid (ACPC); AP7 (2-amino-7-phosphonoheptanoic acid); APV (R-2-amino-5-phosphonopentanoate); CPPene (3-[(R)-2-carboxypiperazin-4-yl]-prop-2-enyl-1-phosphonic acid); (+)-(1S,2S)-1-(4-hydroxy-phenyl)-2-(4-hydroxy-4-phenylpiperidino)-1-pro-p- anol; (1S,2S)-1-(4-hydroxy-3-methoxyphenyl)-2-(4-hydroxy-4-phenylpiperidin- o)-1-propanol; (3R,4S)-3-(4-(4-fluorophenyl)-4-hydroxypiperidin-1-yl-)chroman-4,7-diol; (1R*, 2R*)-1-(4-hydroxy-3-methylphenyl)-2-(4-(4-fluoro-phenyl)-4-hydroxyp- iperidin-1-yl)-propan-1-ol-mesylate; or a salt thereof or combinations thereof.
9. The composition of claim 1, wherein the glutamate receptor antagonist is an NMDA receptor antagonist.
10. The composition of claim 9, wherein the NMDA receptor antagonist is gacyclidine.
11. The composition of claim 9, wherein the NMDA receptor antagonist is an arylcycloalkylamine or a quinazoline.
12. The composition of claim 9, wherein the NMDA receptor antagonist is (S)-ketamine or a salt thereof.
13. The composition of claim 9, wherein the NMDA receptor antagonist is 7-CK or a salt thereof.
14. The composition of claim 1, wherein sustained release of the glutamate receptor antagonist into the cochlea occurs for a period of at least 7 days.
15. The composition of claim 1, wherein sustained release of the glutamate receptor antagonist into the cochlea occurs for a period of at least 10 days.
16. The composition of claim 1, wherein the otic disorder is tinnitus.
17. The composition of claim 1, wherein the composition provides a practical osmolarity from 250 mOsm/L to 320 mOsm/L.
18. The composition of claim 1, wherein the composition has a pH of 7.0-8.0.
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.